Skip to main content
. 2020 Aug 9;111(10):3416–3425. doi: 10.1111/cas.14579

Figure 5.

Figure 5

High CCAR2 expression (red lines) predicted favorable survival outcomes in A, breast, B, colon, and C, prostate cancer, but poor survival in D, large B‐cell lymphoma, E, kidney clear cell carcinoma, and F, renal chromophobe carcinoma. Results from The Cancer Genome Atlas (TCGA) database indicating overall patient survival (OS), except for recurrence‐free survival (RFS) in panel C